18F-FDG PET/CT中骨髓与肿瘤放射组学特征对非小细胞肺癌预后预测的影响
本研究回顾性分析两个队列共227例非小细胞肺癌患者,从治疗前18F-FDG PET/CT图像中提取原发肿瘤、肿瘤周围晕及L3-L5椎体骨髓的放射组学特征。在训练队列中构建并锁定Cox比例风险模型,并在独立队列中进行时间验证。整合分期、骨髓纹理特征及肿瘤/晕纹理特征的模型对无病生存的预测优于仅用临床特征,并在验证队列中验证了其预测价值。
要点
- 治疗前18F-FDG PET/CT中骨髓及肿瘤/晕的放射组学纹理特征可提升非小细胞肺癌无病生存预测。
- 完全整合模型在训练队列一致性为0.78,在独立验证队列为0.72,并可二分类分层风险。
- 在临床分期模型基础上,加入肿瘤区域特征或骨髓特征均能进一步改善预测效能。
核心结论
- 包含治疗前18F-FDG PET纹理特征(原发肿瘤、肿瘤周围晕和骨髓)的模型比仅用临床特征更准确地预测非小细胞肺癌患者的无病生存。
研究设计与样本
- 回顾性分析两个独立队列(2008年至2016年收集),共227例患者,其中训练队列136例(平均年龄69岁±9,101例男性),时间验证队列91例(平均年龄72岁±10,91例男性);在治疗前FDG PET/CT图像上勾画每个肿瘤、其周围晕及L3-L5椎体骨髓,从PET序列计算156个骨髓放射组学特征和512个肿瘤及晕放射组学特征;采用最小绝对收缩和选择算子(LASSO)随机稀疏Cox回归在训练队列中筛选预测无病生存的特征,构建并锁定Cox比例风险模型,然后在独立队列中进行时间验证。
诊断标准与关键数值
- 最佳临床模型包括分期;仅加入肿瘤区域特征即改善结局预测(对数似然,-158 vs -152;P = .007);再加入骨髓特征继续改善性能(对数似然,-158 vs -145;P = .001);顶级模型整合分期、两个骨髓纹理特征、一个肿瘤伴晕纹理特征和两个晕纹理特征(一致性0.78;95%CI:0.70,0.85;P < .001);该完全整合模型在独立队列中预测不良结局(一致性0.72;95%CI:0.64,0.80;P < .001),且二元评分将患者分为不良结局高风险和低风险(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Primary tumor maximum standardized uptake value is a prognostic marker for non-small cell lung cancer. In the setting of malignancy, bone marrow activity from fluorine 18-fluorodeoxyglucose (FDG) PET may be informative for clinical risk stratification. Purpose To determine whether integrating FDG PET radiomic features of the primary tumor, tumor penumbra, and bone marrow identifies lung cancer disease-free survival more accurately than clinical features alone. Materials and Methods Patients were retrospectively analyzed from two distinct cohorts collected between 2008 and 2016. Each tumor, its surrounding penumbra, and bone marrow from the L3-L5 vertebral bodies was contoured on pretreatment FDG PET/CT images. There were 156 bone marrow and 512 tumor and penumbra radiomic features computed from the PET series. Randomized sparse Cox regression by least absolute shrinkage and selection operator identified features that predicted disease-free survival in the training cohort. Cox proportional hazards models were built and locked in the training cohort, then evaluated in an independent cohort for temporal validation. Results There were 227 patients analyzed; 136 for training (mean age, 69 years ± 9 [standard deviation]; 101 men) and 91 for temporal validation (mean age, 72 years ± 10; 91 men). The top clinical model included stage; adding tumor region features alone improved outcome prediction (log likelihood, -158 vs -152; P = .007). Adding bone marrow features continued to improve performance (log likelihood, -158 vs -145; P = .001). The top model integrated stage, two bone marrow texture features, one tumor with penumbra texture feature, and two penumbra texture features (concordance, 0.78; 95% confidence interval: 0.70, 0.85; P < .001). This fully integrated model was a predictor of poor outcome in the independent cohort (concordance, 0.72; 95% confidence interval: 0.64, 0.80; P < .001) and a binary score stratified patients into high and low risk of poor outcome (P < .001). Conclusion A model that includes pretreatment fluorine 18-fluorodeoxyglucose PET texture features from the primary tumor, tumor penumbra, and bone marrow predicts disease-free survival of patients with non-small cell lung cancer more accurately than clinical features alone. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Mattonen SA, Davidzon GA, Benson J, et al. Bone Marrow and Tumor Radiomics at 18F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer. Radiology. 2019. PMID: 31526257. doi:10.1148/radiol.2019190357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。